The commitment is in the same line as the price
Both figures in the homepage hero carry an asterisk, and the asterisk resolves in the same block to a statement that a three-month treatment commitment is required. A reader cannot see the price without seeing the condition.
That is worth more than it sounds. A plan term hidden a click away is the single most common way a headline figure in this category stops being true, and this seller has closed it off in the most visible place on the site.
Both figures are floors
Each price is a starting figure and neither carries a dose. Nothing on the site says what a maintenance month costs or how far the number moves as the dose climbs, so the commitment disclosure is better than the price disclosure it attaches to.
The adolescent programme page quotes a first-month figure that differs from the adult starting rate, and neither page reconciles the two.
A compounded product described as approved
The teen programme page describes FDA-approved semaglutide and tirzepatide. The rest of the site describes compounded preparations made to order by 503A compounding pharmacies. Those are not the same thing, and a compounded preparation is not an FDA-approved finished drug product.
That contradiction matters most where it appears. A parent deciding for a twelve-year-old is the last reader who should have to work out which description governs, and the site never resolves it.
Coverage stated, sourcing not
The clinic states it provides telemedicine care across all fifty states, which is a broader claim than the California in its name suggests and is stated plainly enough to record.
The compounding pharmacies are named only by licensing class. No individual prescribing clinician or medical director is identified. Nothing states whether a membership applies on top of the monthly figure, and a separately priced consultation appears on the teen page.
California Trim Clinic's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $199/mostarting at, per month, with a footnote in the same line stating that a three-month treatment commitment is required | September 2026source |
| Tirzepatide (compounded) | $299/mostarting at, per month, with a footnote in the same line stating that a three-month treatment commitment is required | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 283 providers reviewed here are paid partners today; the other 279 are not. See how this works.
See California Trim Clinic's current price →Good fit if
- Readers who can commit to a full quarter and want that condition stated beside the number.
- Patients in smaller markets, given the stated fifty-state telemedicine footprint.
- Families looking for an adolescent programme documented separately rather than treated as an adult one scaled down.
- Anyone who wants the 503A compounding route stated rather than implied.
Look elsewhere if
- Anyone wanting to try a single month; a three-month commitment is required for both advertised rates.
- Parents who need to know whether their child would receive an approved product or a compounded one, which this site describes both ways.
- Readers who need the compounding pharmacy named or a prescriber identified.
- Anyone who needs to know the maintenance-dose price, which is not published.
How this review was verified
- Read the homepage, the semaglutide page and the adolescent programme page at their source URLs and logged each figure with the date it was read.
- Carried the three-month commitment footnote into both price qualifiers so the condition travels with the number.
- Compared the adolescent page description of an FDA-approved medication against the compounded 503A framing used elsewhere on the site and recorded the contradiction rather than resolving it.
- Recorded the fifty-state telemedicine claim as stated, and the pharmacy, prescriber and membership positions as gaps.
- Pulled all 3,677 rows of the FDA warning-letter table and filtered them locally with a known-positive and a nonsense-string control in the same run; no letter found.